Journal
JOURNAL OF CRITICAL CARE
Volume 26, Issue 1, Pages 3-10Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.jcrc.2010.04.001
Keywords
Ventilator-associated pneumonia; Care bundles; Diagnosis; Therapy
Categories
Funding
- Pfizer
- Johnson Johnson
- Merck
- Astra Zeneca
- Wyeth
- Roche Diagnostics
- Becton Dickinson
- Chiron-Novartis
- GeneOhm
- BioMerieux
- Bayer
- Sanofi-Aventis
- Intermune
- Daiichi
- Astellas
- Glaxo-SmithKline
- Boehringer Ingelheim
- Wyeth International
- Instituto Salud Carlos III [FISS 06/0060]
- IISPV
Ask authors/readers for more resources
Background: Although there is a wealth of guidance concerning the management of patients with ventilator-associated pneumonia (VAP), compliance with recommendations concerning optimal treatment practices is highly variable. Methods: This document presents a comprehensive care bundle package addressing all aspects of VAP diagnosis and treatment in an attempt to promote guideline-compliant practices. Uniquely, the development of these care bundles used a formalized method to assess the supporting data, based on multicriteria decision analysis. Results: This system allowed the numerous VAP management parameters identified from recent European guidelines to be ranked according to defined criteria. The resulting VAP care bundles are (a) diagnosis: early chest x-rays within 1 hour, immediate reporting of respiratory secretions Gram staining, and (b) therapy: immediate treatment, empiric therapy based on local pathogens and risk factors, de-escalation, assessment of response within 72 hours, and short therapy duration if feasible. Conclusion: Adoption of these care bundles should rationalize VAP management practices and facilitate the development of consistent and guideline-compliant care processes. (C) 2011 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available